Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Yangsan-si, Korea, Republic of Clinical Trials

A listing of Yangsan-si, Korea, Republic of clinical trials actively recruiting patients volunteers.

RESULTS

Found (5) clinical trials

A Study Evaluating the Safety Pharmacokinetics and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic HBV

This is a Phase 2, open-label, randomized, multiple dose, varied administration regimen study with 2 parts (Parts A and B). Part A will utilize an ascending dose cohort design with sequential cohorts. Each cohort will be evaluated by the DSMB for safety. Additional cohorts may be added by the DSMB ...

Phase

0.0 miles

Learn More »

Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

This study is designed to be multi-center, open-label, single-arm, prospective, phase II trial of patient with sensitizing EGFR mutation positive Non-Squamous Cell Carcinoma patients who previously treated with EGFR TKI and cytotoxic chemotherapy. Approximately 69 patients will be enrolled into the trial, and expected study duration is 48 months from ...

Phase

0.0 miles

Learn More »

Continuous IntraVenous Infusion of Ketamine in Terminally Ill Cancer Patients

There are approximately 20 percent patients of refractory cancer pain, which is troubled with uncontrolled pain though treatment including opioids. Ketamine has been showed the performance of Ketamine, N-methyl-D-aspartate (NMDA) receptor blocker, in refractory cancer pain based on prior studies. We cannot yet confirm the role of Ketamine comparing the ...

Phase

0.0 miles

Learn More »

The objective of this study is to assess efficacy and safety of radium 223 dichloride in subjects with human epidermal growth factor receptor 2 (HER2) negative hormone receptor positive breast cancer with bone metastases treated with exemestane and everolimus.

Phase

8.88 miles

Learn More »

The objective of this study is to assess efficacy and safety of radium-223 dichloride in subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone receptor positive breast cancer with bone metastases treated with hormonal treatment background therapy.

Phase

8.88 miles

Learn More »